<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03843970</url>
  </required_header>
  <id_info>
    <org_study_id>CoLeBu</org_study_id>
    <nct_id>NCT03843970</nct_id>
  </id_info>
  <brief_title>Hemodynamic Safety of Levobupivacaine vs Bupivacaine in Patients Over 65 Years Undergoing Hip Surgery</brief_title>
  <official_title>Hemodynamic Safety of Isobaric Levobupivacaine Versus Isobaric Bupivacaine for Subarachnoid Anesthesia in Patients Over 65 Years Undergoing Hip Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clínico Universitario de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clínico Universitario de Valencia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The altered hemodynamics, and therefore the arterial hypotension is the most prevalent
      adverse effect after subarachnoid anesthesia. The objective of the study was to determine the
      exact role of local anesthetic selection underlying spinal anesthesia-induced hypotension in
      the elderly patient. We conducted a descriptive, interventional pilot study to assess the
      hemodynamic impact of subarachnoid anesthesia with isobaric levobupivacaine versus isobaric
      bupivacaine for hip fracture surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Objective of the trial 1.1. Main objective: Compare the hemodynamic effects from
           invasive systolic diastolic and mean blood pressures (ISBP, IDBP and IMBP) mesured in
           mmHg, arterial partial pressure of oxygen (PaO2) and arterial partial pressure of carbon
           dioxide (PaCO2) measured in mmHg , arterial oxygen saturation (SatO2) measured in%,
           heart rate (HR / bpm) measured in beats per minute.

           Other variables of interest will be: cardiac index (CI) mesured in litres per minute per
           square metre (L/min/m2), peripheral vascular resistance (PVR) medured in
           dynes/seconds/cm-5, partial arterial pressure of oxygen (PaO2) and arterial partial
           pressure of carbon dioxide (PaCO2) measured in mmHg, pH (pH), arterial lactate (Lc)
           measured in mmol / L, arterial hemoglobin (Hb) measured in g/dl, partial oxygen
           saturation (SpO2%) measured in %.

           1.2. Secondary objectives: Assess potential adverse events during surgery and 48 hours
           of surgery. Adverse events include adverse cardiovascular and respiratory rate, events
           related to both surgical and anesthetic techniques and exitus.

        2. End points 2.1. Primary end point(s): hemodynamic variables invasive systolic blood
           pressure (ISBP) measured in mmHg invasive diastolic blood pressure (ISBP), measured in
           mmHg invasive mean blood pressure (IMBP), measured in mmHg arterial partial pressure of
           oxygen (PaO2) arterial partial pressure of carbon dioxide (PaCO2), measured in mmHg
           arterial oxygen saturation (SatO2) measured in% heart rate (HR / bpm) measured in beats
           per minute cardiac index (CI) mesured in litres per minute per square metre (L/min/m2).
           peripheral vascular resistance (PVR) mesured in dynes/seconds/cm-5 partial arterial
           pressure of oxygen (PaO2) measured in mmHg arterial partial pressure of carbon dioxide
           (PaCO2) measured in mmHg pH (pH) arterial lactate (Lc) measured in mmol / L arterial
           hemoglobin (Hb) measured in g / dl partial oxygen saturation (SpO2%) measured in %.

      2.1.1 Timepoint(s) of evaluation of this end point: entry into the operating room, after 30
      minutes of anesthesia and at the end of anesthesia.

      2.2. Secondary end point(s):

      A. Intraoperative adverse events:

        1. Cardiovascular and Respiratory: Venous air embolism (VAE), deep vein thrombosis (DVT),
           myocardial infarction (AMI), cerebrovascular accident (CVA), congestive heart failure
           (CHF), pneumonia (N), Exitus (Ex)

        2. Other: Acute renal failure (ARF), vomiting (V)

        3. Associated with the surgical technique: RBC transfusion (Th), plasma transfusion (TPL),
           nerve damage (ln), femur fracture (Fx f)

        4. Associated with the anesthetic technique: paresthesia (pair), hematic puncture (ph),
           other.

      B.Postoperative adverse events (at 48 hours)

        1. Cardiovascular and Respiratory: Deep vein thrombosis (DVT), myocardial infarction (AMI),
           cerebrovascular accident (CVA), congestive heart failure (CHF), pneumonia (N), Exitus
           (Ex)

        2. Other: Acute renal failure (ARF), UTI (Infu), vomiting (V).

        3. Associated with the surgical technique: RBC transfusion (Th), plasma transfusion (TPL),
           neurologic deficit (defnq), surgical wound infection (Infhq).

        4. Associated with the anesthetic technique: neurological deficit (defn), postdural
           puncture headache (PDPH), back pain (Lumb).

      2.2.1. Timepoint(s) of evaluation of this end point: 48 hours of surgery
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare hemodynamic effects from invasive systolic pressure, invasive diastolic pressure and mean blood pressure.</measure>
    <time_frame>Intraoperative</time_frame>
    <description>The measurement of invasive systolic pressure and invasive diastolic pressure and mean blood pressure mesured in mmHg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare hemodynamic effects from heart rate.</measure>
    <time_frame>Intraoperative</time_frame>
    <description>The measurement of heart rate in beats per minute.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>48 hours of surgery</time_frame>
    <description>Adverse events include adverse cardiovascular and respiratory rate, events related to both surgical and anesthetic techniques.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hip Fractures</condition>
  <condition>Hemodynamic Stability</condition>
  <arm_group>
    <arm_group_label>Levobupivacaine Hydrochloride 0,5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The doses used of Levobupivacaine Hydrochloride 0.5% will be 6 mg and the dose of fentanyl 10 μg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isobaric bupivacaine 0,5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The doses used of isobaric bupivacaine will be 6 mg and the dose of fentanyl 10 μg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine Hydrochloride 0.5%</intervention_name>
    <description>The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.</description>
    <arm_group_label>Levobupivacaine Hydrochloride 0,5%</arm_group_label>
    <other_name>L solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isobaric bupivacaine 0.5%</intervention_name>
    <description>The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.</description>
    <arm_group_label>isobaric bupivacaine 0,5%</arm_group_label>
    <other_name>B solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Women over 65 years

          -  Who meet the requirements in the pre-anesthetic to be treated with spinal anesthesia
             with levobupivacaine or bupivacaine, both with fentanyl,

          -  Fitness: from I to IV, according to the American Society of Anesthesiologists (ASA),

          -  Weight&gt; 40 kg,

          -  Height&gt; 140 cm,

          -  Body mass index (BMI) &lt;50 kg/m2,

          -  Pathology cardiovascular, respiratory, renal and endocrine-metabolic,

          -  Provide written informed consent

        Exclusion Criteria:

          -  Patients with uncontrolled hypertension (non-invasive systolic blood pressure&gt; 180
             mmHg and / or non-invasive diastolic blood pressure &gt; 110mmHg),

          -  HR&gt; 120 bpm,

          -  SpO2 &lt;90% on arrival in the operating room and the contraindication to perform
             neuraxial anesthesia (patient refusal, infection at the site of puncture or lancing
             different, neuromuscular degenerative disease, hypovolemia, coagulopathy or
             anticoagulant therapy, morbid obesity, and extreme increase in intracranial pressure).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HERRERA ROSA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valencia University General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HERRERA Rosa, PhD</last_name>
    <phone>+34 659205338</phone>
    <email>35606rhc@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BELDA Fco Javier, Professor</last_name>
    <phone>+34 961.973.500</phone>
    <phone_ext>973847</phone_ext>
    <email>Fco.Javier.Belda@uv.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínico Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HERRERA ROSA, PhD</last_name>
      <phone>+34961.973.500</phone>
      <email>35606rhc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>TORNERO CARLOS, PhD</last_name>
      <phone>+34961.973.500</phone>
      <email>carlos.tornero@uv.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clínico Universitario de Valencia</investigator_affiliation>
    <investigator_full_name>ROSA HERRERA, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hip fracture, Subarachnoid block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

